PE20000042A1 - Uso combinado de un inhibidor de farnesilo transferasa y un agente antineoplasico y/o terapia de radiacion para el tratamiento de enfermedades proliferativas - Google Patents
Uso combinado de un inhibidor de farnesilo transferasa y un agente antineoplasico y/o terapia de radiacion para el tratamiento de enfermedades proliferativasInfo
- Publication number
- PE20000042A1 PE20000042A1 PE1998001263A PE00126398A PE20000042A1 PE 20000042 A1 PE20000042 A1 PE 20000042A1 PE 1998001263 A PE1998001263 A PE 1998001263A PE 00126398 A PE00126398 A PE 00126398A PE 20000042 A1 PE20000042 A1 PE 20000042A1
- Authority
- PE
- Peru
- Prior art keywords
- cancer
- myeloid
- treatment
- proliferative diseases
- antineoplastic agent
- Prior art date
Links
- 229940034982 antineoplastic agent Drugs 0.000 title abstract 2
- 239000002246 antineoplastic agent Substances 0.000 title abstract 2
- 201000010099 disease Diseases 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 2
- 230000002062 proliferating effect Effects 0.000 title abstract 2
- 229940123468 Transferase inhibitor Drugs 0.000 title 1
- 238000001959 radiotherapy Methods 0.000 title 1
- 239000003558 transferase inhibitor Substances 0.000 title 1
- -1 CITARABIN Chemical compound 0.000 abstract 4
- 206010028980 Neoplasm Diseases 0.000 abstract 4
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 abstract 4
- 201000011510 cancer Diseases 0.000 abstract 4
- 108010092160 Dactinomycin Proteins 0.000 abstract 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 abstract 2
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 abstract 2
- 229960000640 dactinomycin Drugs 0.000 abstract 2
- 239000003112 inhibitor Substances 0.000 abstract 2
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- FPVKHBSQESCIEP-UHFFFAOYSA-N (8S)-3-(2-deoxy-beta-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol Natural products C1C(O)C(CO)OC1N1C(NC=NCC2O)=C2N=C1 FPVKHBSQESCIEP-UHFFFAOYSA-N 0.000 abstract 1
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 abstract 1
- IDPUKCWIGUEADI-UHFFFAOYSA-N 5-[bis(2-chloroethyl)amino]uracil Chemical compound ClCCN(CCCl)C1=CNC(=O)NC1=O IDPUKCWIGUEADI-UHFFFAOYSA-N 0.000 abstract 1
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 abstract 1
- 108010006654 Bleomycin Proteins 0.000 abstract 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 abstract 1
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 abstract 1
- 206010009944 Colon cancer Diseases 0.000 abstract 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 abstract 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 abstract 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 abstract 1
- 206010024291 Leukaemias acute myeloid Diseases 0.000 abstract 1
- GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 abstract 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 abstract 1
- 102000029749 Microtubule Human genes 0.000 abstract 1
- 108091022875 Microtubule Proteins 0.000 abstract 1
- 108010038807 Oligopeptides Proteins 0.000 abstract 1
- 102000015636 Oligopeptides Human genes 0.000 abstract 1
- 229910019142 PO4 Inorganic materials 0.000 abstract 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 abstract 1
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 abstract 1
- 102000004357 Transferases Human genes 0.000 abstract 1
- 108090000992 Transferases Proteins 0.000 abstract 1
- 229940122803 Vinca alkaloid Drugs 0.000 abstract 1
- CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical class [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 abstract 1
- 239000003242 anti bacterial agent Substances 0.000 abstract 1
- 229940088710 antibiotic agent Drugs 0.000 abstract 1
- 229960001561 bleomycin Drugs 0.000 abstract 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 abstract 1
- 229960002092 busulfan Drugs 0.000 abstract 1
- 229960005243 carmustine Drugs 0.000 abstract 1
- 239000012829 chemotherapy agent Substances 0.000 abstract 1
- 229960004630 chlorambucil Drugs 0.000 abstract 1
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 abstract 1
- 208000029742 colonic neoplasm Diseases 0.000 abstract 1
- 229960004397 cyclophosphamide Drugs 0.000 abstract 1
- 229960003901 dacarbazine Drugs 0.000 abstract 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 abstract 1
- 229960000975 daunorubicin Drugs 0.000 abstract 1
- 229960004679 doxorubicin Drugs 0.000 abstract 1
- ODKNJVUHOIMIIZ-RRKCRQDMSA-N floxuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ODKNJVUHOIMIIZ-RRKCRQDMSA-N 0.000 abstract 1
- 229960000961 floxuridine Drugs 0.000 abstract 1
- 229960002949 fluorouracil Drugs 0.000 abstract 1
- 230000003325 follicular Effects 0.000 abstract 1
- 230000004927 fusion Effects 0.000 abstract 1
- 229960001101 ifosfamide Drugs 0.000 abstract 1
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 abstract 1
- 229960002247 lomustine Drugs 0.000 abstract 1
- 201000005202 lung cancer Diseases 0.000 abstract 1
- 208000020816 lung neoplasm Diseases 0.000 abstract 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 abstract 1
- 229960004961 mechlorethamine Drugs 0.000 abstract 1
- HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical compound ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 abstract 1
- 201000001441 melanoma Diseases 0.000 abstract 1
- 229960001924 melphalan Drugs 0.000 abstract 1
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 abstract 1
- 229960001428 mercaptopurine Drugs 0.000 abstract 1
- 229960000485 methotrexate Drugs 0.000 abstract 1
- 210000004688 microtubule Anatomy 0.000 abstract 1
- 208000025113 myeloid leukemia Diseases 0.000 abstract 1
- 201000002528 pancreatic cancer Diseases 0.000 abstract 1
- 208000008443 pancreatic carcinoma Diseases 0.000 abstract 1
- FPVKHBSQESCIEP-JQCXWYLXSA-N pentostatin Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC[C@H]2O)=C2N=C1 FPVKHBSQESCIEP-JQCXWYLXSA-N 0.000 abstract 1
- 229960002340 pentostatin Drugs 0.000 abstract 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 abstract 1
- 239000010452 phosphate Substances 0.000 abstract 1
- 229960000952 pipobroman Drugs 0.000 abstract 1
- NJBFOOCLYDNZJN-UHFFFAOYSA-N pipobroman Chemical compound BrCCC(=O)N1CCN(C(=O)CCBr)CC1 NJBFOOCLYDNZJN-UHFFFAOYSA-N 0.000 abstract 1
- 229960001052 streptozocin Drugs 0.000 abstract 1
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 abstract 1
- 229960004964 temozolomide Drugs 0.000 abstract 1
- 210000001685 thyroid gland Anatomy 0.000 abstract 1
- 229950001353 tretamine Drugs 0.000 abstract 1
- IUCJMVBFZDHPDX-UHFFFAOYSA-N tretamine Chemical compound C1CN1C1=NC(N2CC2)=NC(N2CC2)=N1 IUCJMVBFZDHPDX-UHFFFAOYSA-N 0.000 abstract 1
- 229960001055 uracil mustard Drugs 0.000 abstract 1
- JXLYSJRDGCGARV-CFWMRBGOSA-N vinblastine Chemical compound C([C@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-CFWMRBGOSA-N 0.000 abstract 1
- 229960003048 vinblastine Drugs 0.000 abstract 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 abstract 1
- 229960004528 vincristine Drugs 0.000 abstract 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
SE REFIERE AL USO DE a)UN INHIBIDOR DE LA FARNESILO TRANSFERASA (FPT) TAL COMO BENZOCICLOHEPTAPIRIDINA TRICICLICA DE ANILLO FUSIONADO, OLIGOPEPTIDO, PEPTIDO MIMETICO, PEPTIDO MIMETICO FARNESILADO O UN DERIVADO FARNESILADO; b)UN AGENTE ANTINEOPLASICO, QUE AFECTA A LOS MICROTUBULOS TAL COMO MOSTAZA DE URACILO, CLORMETINA, CICLOFOSFAMIDA, IFOSFAMIDA, MELPHALAN, CLORAMBUCILO, PIPOBROMANO, TRIETILENEMELAMINA, TRIETILENTIOFOSFORAMINA, BUSULFAN, CARMUSTINA, LOMUSTINA, ESTREPTOZOCINA, DACARBAZINA, METOTREXATO, 5-FLUORURACILO, FLOXURIDINA, CITARABINA, 6-MERCAPTOPURINA, FOSFATO DE FLUDARABINA, PENTOSTATINA, TEMOZOLOMIDA, VINBLASTINA, VINDESINA, BLEOMICINA, DACTINOMICINA, DAUNORUBICINA, DOXORUBICINA, VINCRISTINA, GEMCITABINA, PACLITAXEL, TAXOTERE, ENTRE OTROS; CUANDO EL INHIBIDOR DE FPT DE FORMULA A, DONDE X` ES H, HALO; Y' ES H, -COOR'; R' ES ALQUILO C1-C12, FENILO, ALQUILARILO, 2-PIPERIDILO, ENTRE OTROS; EL AGENTE QUIMIOTERAPICO NO ES ALCALOIDE DE LA VINCA, EPIPODOFILLOTOXINAS, ANTIBIOTICOS DE ANTRACICLINA, ACTINOMICINA D, ENTRE OTROS; LA COMBINACION PUEDE SER UTIL PARA EL TRATAMIENTO DE ENFERMEDADES PROLIFERATIVAS COMO CANCER DE PULMON, CANCER PANCREATICO, CANCER DE COLON, LEUCEMIA MIELOIDE, MELANOMA, CANCER FOLICULAR DE TIROIDE, CARCINOMA DE VESICULA, GLIOMA, SINDROME MIELODISPLASTICO, CANCER DE MAMA, CANCER DE PROSTATA
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US99602797A | 1997-12-22 | 1997-12-22 | |
| US14352998A | 1998-08-28 | 1998-08-28 | |
| US18196998A | 1998-10-29 | 1998-10-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20000042A1 true PE20000042A1 (es) | 2000-02-17 |
Family
ID=27385940
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE1998001263A PE20000042A1 (es) | 1997-12-22 | 1998-12-21 | Uso combinado de un inhibidor de farnesilo transferasa y un agente antineoplasico y/o terapia de radiacion para el tratamiento de enfermedades proliferativas |
Country Status (25)
| Country | Link |
|---|---|
| EP (1) | EP1041985B1 (es) |
| JP (1) | JP4502503B2 (es) |
| KR (1) | KR100700907B1 (es) |
| CN (1) | CN1129431C (es) |
| AR (1) | AR017440A1 (es) |
| AT (1) | ATE317697T1 (es) |
| AU (1) | AU756762B2 (es) |
| BR (1) | BR9814419A (es) |
| CA (1) | CA2315693C (es) |
| CL (1) | CL2007001889A1 (es) |
| CO (1) | CO5080764A1 (es) |
| CZ (1) | CZ298511B6 (es) |
| DE (1) | DE69833509T2 (es) |
| DK (1) | DK1041985T3 (es) |
| ES (1) | ES2255196T3 (es) |
| HU (1) | HUP0102473A3 (es) |
| IL (1) | IL136462A0 (es) |
| MY (1) | MY137303A (es) |
| NO (1) | NO326832B1 (es) |
| NZ (1) | NZ504928A (es) |
| PE (1) | PE20000042A1 (es) |
| PT (1) | PT1041985E (es) |
| SK (1) | SK285584B6 (es) |
| TW (1) | TW581763B (es) |
| WO (1) | WO1999032114A1 (es) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2787327B1 (fr) * | 1998-12-21 | 2003-01-17 | Aventis Pharma Sa | Compositions contenant des inhibiteurs de farnesyle transferase |
| CA2390317C (fr) * | 1999-11-09 | 2010-03-23 | Gregoire Prevost | Produit comprenant un inhibiteur de la transduction des signaux des proteines g heterotrimeriques en association avec un autre agent anti-cancereux pour une utilisation therapeutique dans le traitement du cancer |
| WO2001045740A2 (en) * | 1999-12-22 | 2001-06-28 | The Government Of The United States, Department Of Health And Human Services | Compositions and methods for treatment of breast cancer |
| AU2001256166A1 (en) * | 2000-02-29 | 2001-09-12 | Janssen Pharmaceutica N.V. | Farnesyl protein transferase inhibitor combinations with anti-tumor nucleoside derivatives |
| JP2003525246A (ja) * | 2000-02-29 | 2003-08-26 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | 白金化合物とのファルネシルタンパク質トランスフェラーゼ阻害剤の組み合わせ剤 |
| US20030078281A1 (en) * | 2000-02-29 | 2003-04-24 | Rybak Mary Ellen Margaret | Farnesyl protein transferase inhibitor combinations with anti-tumor alkylating agents |
| EP1267871A2 (en) * | 2000-02-29 | 2003-01-02 | Janssen Pharmaceutica N.V. | Farnesyl protein transferase inhibitor combinations with anti-tumor podophyllotoxin derivatives |
| AU2001244167A1 (en) * | 2000-02-29 | 2001-09-12 | Janssen Pharmaceutica N.V. | Farnesyl protein transferase inhibitor combinations with anti-tumor anthracycline derivatives |
| EP1263437A2 (en) * | 2000-02-29 | 2002-12-11 | Janssen Pharmaceutica N.V. | Farnesyl protein transferase inhibitor combinations with vinca alkaloids |
| TWI310684B (en) | 2000-03-27 | 2009-06-11 | Bristol Myers Squibb Co | Synergistic pharmaceutical kits for treating cancer |
| US6645966B2 (en) * | 2001-01-22 | 2003-11-11 | Schering Corporation | Treatment of malaria with farnesyl protein transferase inhibitors |
| DE60230017D1 (de) * | 2001-02-15 | 2009-01-08 | Janssen Pharmaceutica Nv | Farnesyl-protein-transferase hemmer in kombination mit antiöstrogenen |
| EP1448268A2 (en) * | 2001-11-30 | 2004-08-25 | Schering Corporation | Use of an farnesyl protein transferase inhibitor in combination with other antineoplastic agents for the manufacture of a medicament against cancer |
| US20040006087A1 (en) * | 2001-12-03 | 2004-01-08 | Schering Corporation | Method of treating cancer using FPT inhibitors and antineoplastic agents |
| WO2008022535A1 (fr) * | 2006-08-09 | 2008-02-28 | Tian Jin Tasly Group Co., Ltd. | Composition pharmaceutique pour traiter le gliome du cerveau, son procédé et sa préparation pharmaceutique |
| CN105198758A (zh) * | 2015-09-22 | 2015-12-30 | 湖南大学 | 一种高纯度(z)-他莫昔酚的制备方法 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5047246A (en) * | 1988-09-09 | 1991-09-10 | Bristol-Myers Company | Direct compression cyclophosphamide tablet |
| ATE139447T1 (de) * | 1990-12-18 | 1996-07-15 | Wellcome Found | Mittel zur verstaerkung der wirkung von antitumoralen mittel und zur widerstandsbekaempfung von vielfachdrogen |
| JP2767176B2 (ja) * | 1992-12-15 | 1998-06-18 | 大塚製薬株式会社 | 抗癌剤 |
| US5637688A (en) * | 1994-12-13 | 1997-06-10 | Eli Lilly And Company | Process for preparing 1-(2'-deoxy-2'-difluoro-d-ribofuranosyl)-4-aminopyrimidin-2-one hydrochloride |
| WO1997005902A1 (fr) * | 1995-08-09 | 1997-02-20 | Banyu Pharmaceutical Co., Ltd. | Composition medicinale |
| ATE309238T1 (de) * | 1995-12-22 | 2005-11-15 | Schering Corp | Zur hemming der g-protein-funktion und zur behandlung proliferativer krankheiten geeignete tricyclische amide |
| ES2258790T3 (es) * | 1996-03-12 | 2006-09-01 | Pg-Txl Company, L.P. | Profarmacos de paclitaxel solubles en agua. |
| WO1997036583A1 (en) * | 1996-04-03 | 1997-10-09 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
| EP0910385A4 (en) * | 1996-04-15 | 1999-12-22 | Univ Pennsylvania | Sensitization of cells to radiation and chemotherapy |
| WO1997038664A2 (en) * | 1996-04-18 | 1997-10-23 | Merck & Co., Inc. | A method of treating cancer |
| WO1997045412A1 (en) * | 1996-05-30 | 1997-12-04 | Merck & Co., Inc. | A method of treating cancer |
| EP0967917B1 (en) * | 1997-01-29 | 2005-11-30 | Picker Medical Systems, Ltd. | Predictive bolus tracking |
| NZ337283A (en) * | 1997-02-18 | 2001-02-23 | Canji Inc | Use of a tumor suppressing nucleic acid which encodes wild type p53 or retinoblastoma proteins and paclitaxel derivative or a polyprenyl-protein transferase inhibitor for the treatment of neoplasms |
-
1998
- 1998-12-21 EP EP98963829A patent/EP1041985B1/en not_active Expired - Lifetime
- 1998-12-21 JP JP2000525105A patent/JP4502503B2/ja not_active Expired - Fee Related
- 1998-12-21 IL IL13646298A patent/IL136462A0/xx unknown
- 1998-12-21 MY MYPI98005809A patent/MY137303A/en unknown
- 1998-12-21 PT PT98963829T patent/PT1041985E/pt unknown
- 1998-12-21 HU HU0102473A patent/HUP0102473A3/hu unknown
- 1998-12-21 AR ARP980106565A patent/AR017440A1/es unknown
- 1998-12-21 CO CO98075842A patent/CO5080764A1/es unknown
- 1998-12-21 SK SK898-2000A patent/SK285584B6/sk not_active IP Right Cessation
- 1998-12-21 KR KR1020007006938A patent/KR100700907B1/ko not_active Expired - Fee Related
- 1998-12-21 NZ NZ504928A patent/NZ504928A/xx unknown
- 1998-12-21 AU AU19072/99A patent/AU756762B2/en not_active Ceased
- 1998-12-21 CA CA2315693A patent/CA2315693C/en not_active Expired - Fee Related
- 1998-12-21 AT AT98963829T patent/ATE317697T1/de not_active IP Right Cessation
- 1998-12-21 DK DK98963829T patent/DK1041985T3/da active
- 1998-12-21 DE DE69833509T patent/DE69833509T2/de not_active Expired - Lifetime
- 1998-12-21 BR BR9814419-7A patent/BR9814419A/pt not_active Application Discontinuation
- 1998-12-21 CN CN98813742A patent/CN1129431C/zh not_active Expired - Fee Related
- 1998-12-21 CZ CZ20002236A patent/CZ298511B6/cs not_active IP Right Cessation
- 1998-12-21 PE PE1998001263A patent/PE20000042A1/es not_active Application Discontinuation
- 1998-12-21 ES ES98963829T patent/ES2255196T3/es not_active Expired - Lifetime
- 1998-12-21 TW TW087121355A patent/TW581763B/zh not_active IP Right Cessation
- 1998-12-21 WO PCT/US1998/026224 patent/WO1999032114A1/en active IP Right Grant
-
2000
- 2000-06-21 NO NO20003229A patent/NO326832B1/no not_active IP Right Cessation
-
2007
- 2007-06-27 CL CL2007001889A patent/CL2007001889A1/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20000042A1 (es) | Uso combinado de un inhibidor de farnesilo transferasa y un agente antineoplasico y/o terapia de radiacion para el tratamiento de enfermedades proliferativas | |
| UA42720C2 (uk) | Похідні 10, 11 - метандибензосуберану, хемосенсибілізуюча композиція, спосіб подолання резистентності до протипухлинних ліків та спосіб лікування пухлинних захворювань | |
| ES2118160T3 (es) | Compuestos de azol, su produccion y su uso. | |
| MY131126A (en) | Sulfonamides | |
| ES2170252T3 (es) | Tetrahidroimidazopiridoindoldionas como inhibidores de cgmp especifico pde. | |
| ATE240334T1 (de) | Pyrrolobenzodiazepine | |
| ATE312080T1 (de) | 2-chinolonen enthaltende arzneimittel | |
| ES2168737T3 (es) | Inhibidores de la oxido nitrico sintasa. | |
| AR020250A1 (es) | Compueto de isoxazolinona, composicion farmaceutica que lo comprende y su uso para preparar dicha composicion | |
| SE9704709D0 (sv) | Pharmaceutically active compounds | |
| ES2170102T3 (es) | Aminociclohexilesteres y utilizacion de los mismos. | |
| HK1060067A1 (en) | Compositions for antitumour treatment containing ecteinascidin 743 | |
| ES2164088T3 (es) | Antagonistas de la sustancia p para el tratamiento de la emesis. | |
| YU63699A (sh) | Preparati za tretiranje i prevenciju arterijske tromboze i korišćenje inhibitora faktora xa samog ili u kombinaciji sa plateletnim antiagregacionim agensom | |
| DE60016460D1 (de) | Verwendungen und zusammenstellungen von nitratestern als sedativa | |
| MXPA02012659A (es) | Derivados de pirazindiona condensados. | |
| AR032989A1 (es) | Una composicion farmaceutica util para el tratamiento del cancer | |
| AR012878A1 (es) | Un compuesto derivado de 5'-desoxicitidina, su uso, un proceso para fabricarlo, composiciones farmaceuticas que lo comprende, y un kit que comprende dicha composicion. | |
| ATE153665T1 (de) | Tricyclische inhibitoren von gp ii b iii a rezeptoren | |
| ATE137791T1 (de) | Cyanoacrylat-klebstoffe, die eine chinoide verbindung als polymerstabilisierungsmittel enthalten | |
| AR018162A1 (es) | Pirroles substituidos, composicion farmaceutica y el uso de los mismos para la preparacion de dicha composicion farmaceutica | |
| CO5060424A1 (es) | Nuevos 1h-indazoles 1,5 y 3-0 sustituidos con efecto antias- matico, antialergico, antiinflamatorio, inmunomodulador y neuroprotector, procedimientos para su elaboracion y su aplicacion como medicamentos | |
| GEP20043239B (en) | C10 Carbonate Substituted Taxanes as Antitumor Agents | |
| IL112900A (en) | Intermediates for the preparation of hiv protease inhibitors | |
| ES551390A0 (es) | Mejoras introducidas en un procedimiento para la preparacion de piroxicam o una sal farmaceuticamente aceptable del mismo en forma de composicion anti-inflamatoria mejorada. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |